Enliven Therapeutics moves ELVN-001 closer to Phase 3 as CML drug competition intensifies
Find out how Enliven Therapeutics’ ELVN-001 data and FDA alignment could reshape chronic myeloid leukemia drug development.
Enliven Therapeutics moves closer to Phase 3 as ELVN-001 faces its real test
ELVN-001 has early CML promise and a long cash runway. Phase 3 execution now decides whether Enliven Therapeutics can justify the hype.
Why Merck’s Terns acquisition puts chronic myeloid leukemia back in the oncology dealmaking spotlight
Merck needs more than Keytruda. TERN-701 could make chronic myeloid leukemia a sharper test of its next oncology strategy.
Merck’s Terns deal clears antitrust hurdle as TERN-701 becomes bigger oncology test
Merck cleared one deal hurdle. TERN-701 still has to prove whether chronic myeloid leukemia can justify a $6.7 billion bet.
Can Merck’s $6.7bn Terns takeover turn TERN-701 into a post-Keytruda oncology pillar?
Merck is buying Terns for TERN-701. Read why this CML deal could reshape its hematology strategy and what risks still remain.